Primary Sclerosing Cholangitis (PSC) Epidemiology and Market Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Primary Sclerosing Cholangitis (PSC) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering.

This “Primary Sclerosing Cholangitis (PSC)- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Primary Sclerosing Cholangitis (PSC) Disease Understanding and Treatment Algorithm

The Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Primary Sclerosing Cholangitis (PSC).

Treatment

It covers the details of conventional and current medical therapies available in the Primary Sclerosing Cholangitis (PSC) market for the treatment of the condition. It also provides Primary Sclerosing Cholangitis (PSC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Primary Sclerosing Cholangitis (PSC) Epidemiology

The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Primary Sclerosing Cholangitis (PSC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Primary Sclerosing Cholangitis (PSC) Epidemiology

The epidemiology segment also provides the Primary Sclerosing Cholangitis (PSC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Primary Sclerosing Cholangitis (PSC) Drug Chapters

Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Sclerosing Cholangitis (PSC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Primary Sclerosing Cholangitis (PSC) Market Outlook

The Primary Sclerosing Cholangitis (PSC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis (PSC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Primary Sclerosing Cholangitis (PSC) emerging therapies.

Report Highlights

• In the coming years, Primary Sclerosing Cholangitis (PSC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Primary Sclerosing Cholangitis (PSC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Primary Sclerosing Cholangitis (PSC). Launch of emerging therapies will significantly impact the Primary Sclerosing Cholangitis (PSC) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Primary Sclerosing Cholangitis (PSC)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Key Topics Covered:

1. Key Insights

2. Executive Summary of Primary Sclerosing Cholangitis (PSC)

3. Competitive Intelligence Analysis for Primary Sclerosing Cholangitis (PSC)

4. Primary Sclerosing Cholangitis (PSC): Market Overview at a Glance

5. Primary Sclerosing Cholangitis (PSC): Disease Background and Overview

6. Patient Journey

7. Primary Sclerosing Cholangitis (PSC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Primary Sclerosing Cholangitis (PSC) Treatment

11. Marketed Products

12. Emerging Therapies

13. Primary Sclerosing Cholangitis (PSC): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Primary Sclerosing Cholangitis (PSC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher

Companies Mentioned

• Gilead Sciences
• HighTide Biopharma Pty. Ltd.
• NGM Biopharmaceuticals
• Intercept Pharmaceuticals
• Dr Falk Pharma GmbH

For more information about this report visit https://www.researchandmarkets.com/r/i1ilom

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900